Dogwood Q2 Loss Widens to $11.5M on $6.7M Impairment; Cash Runway to Q4 Readout
DWTX sits 41% above its 52-week low of $1.28.
Summary
Dogwood reported a Q2 net loss of $11.5 million, or $0.34 per share, versus a narrower loss a year ago, driven by a $6.7 million non-cash impairment charge tied to goodwill and IPR&D after a market cap decline. R&D spending rose on the Halneuron Phase 2b CINP study, and G&A increased on higher salaries and franchise fees. Cash of $9.6 million is expected to fund operations through the Phase 2b readout in Q4 2026, with top-line results due in fall 2026. The company also plans to begin enrolling the SP16 study for chemotherapy-induced pain in H2 2026. This follows the Q1 10-Q that showed a narrowed loss and extended runway, but the impairment and wider loss mark a setback. The key near-term event is the Halneuron Phase 2b data in fall 2026, which will determine whether the pipeline justifies the current valuation.
At the time of this announcement, DWTX was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.7M. The 52-week trading range was $1.28 to $9.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.